Sign in →

Test Code ALDOL (ALS) Aldolase, Serum

Reporting Name

Aldolase, S

Useful For

Detection of muscle disease

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red

Specimen Required

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 7 days
  Frozen  14 days

Reference Values

0-16 years: <14.5 U/L

≥17 years: <7.7 U/L

Day(s) and Time(s) Performed

Monday through Saturday; Continuously

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
ALS Aldolase, S 1761-6


Result ID Test Result Name Result LOINC Value
ALS Aldolase, S 1761-6

Clinical Information

Aldolase is necessary for glycolysis in muscle as a "rapid response" pathway for production of adenosine triphosphate, independent of tissue oxygen.


Aldolase catalyses the conversion of fructose 1,6-diphosphate into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate, an important reaction in the glycolytic breakdown of glucose to lactate in muscle.


Aldolase is a tetramer whose primary structure depends upon the tissue from which it was synthesized (liver, muscle, brain). The brain form of aldolase has, because of its preponderance in white cells, been suggested to be a leukemia marker, but this is not confirmed.


Elevated values are found in muscle diseases, such as Duchenne muscular dystrophy, dermatomyositis, polymyositis, and limb-girdle dystrophy.


The highest levels of aldolase are found in progressive (Duchenne) muscular dystrophy. Lesser elevations are found in dermatomyositis, polymyositis, and limb-girdle dystrophy. In dystrophic conditions causing hyperaldolasemia, the increase in aldolase becomes less dramatic as muscle mass decreases.


Reference (normal) values are observed in polio, myasthenia gravis, and multiple sclerosis.


Aldolase increases in myocardial infarction in a time pattern similar to the aspartate aminotransferase.


Increases are also associated with acute viral hepatitis, but levels are normal or slightly elevated in chronic hepatitis, portal cirrhosis, and obstructive jaundice.


Elevations may also be seen with gangrene, prostate tumors, trichinosis, some carcinomas metastatic to the liver, some chronic leukemias, some blood dyscrasias, and delirium tremens.


No significant cautionary statements

Method Description

Aldolase catalyzes the splitting of D-fructose 1,6-diphosphate into 2 molecules of triosephosphate, 1 of which is D-glyceraldehyde. The addition of triosephosphate isomerase converts the glyceraldehyde to dihydroxyacetone, which in turn is converted to alpha-glycerol phosphate by the further addition of alpha-glycerol phosphate dehydrogenase. This last enzymatic step also involves the conversion of NADH (reduced nicotinamide adenine dinucleotide) to NAD with a progressive loss of the characteristic absorbance of NADH at 340 nm. This conversion of NADH is measured kinetically.(Pinto PV, Kaplan A, Van Dreal PA: Aldolase. II. Spectrophotometric determination using an ultraviolet procedure. Clin Chem 1969;15:349-360)

Analytic Time

1 day (not reported on Sunday)

Specimen Retention Time

7 days

Reject Due To

Gross hemolysis


Gross lipemia


Gross icterus


NY State Approved


Method Name

Ultraviolet, Kinetic


If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.